Questions answered
Ipamorelin, question by question.
Direct, cited answers to the most-asked questions about ipamorelin's pharmacokinetics, effects, and regulatory status.
How to reconstitute CJC-1295 ipamorelin 5mg?
Reconstitution is a research-handling step, not a clinical procedure, and the specifics depend on the supplier's stated mass and intended working concentration. In general, lyophilized peptide is reconstituted with bacteriostatic water added slowly down the vial wall, swirled rather than shaken, and kept refrigerated because peptides degrade with heat and freeze-thaw. This site gives no human-use preparation or dose.
How long does ipamorelin stay in your system?
About 2 hours, measured as the terminal half-life in healthy human volunteers given intravenous ipamorelin [2]. After roughly five half-lives — around 10 hours — it is essentially cleared from the bloodstream. Clearance is 0.078 L/h/kg and the steady-state volume of distribution is 0.22 L/kg, meaning it stays largely in the blood rather than diffusing into tissue [2].
How long does it take for ipamorelin to work?
Hormonally, fast: the growth-hormone pulse it triggers peaks about 40 minutes after dosing in the human study [2]. That is the measured onset. The subjective effects users report — better sleep, faster recovery — are described building over one to two weeks, but those are anecdotal community accounts, not clinical findings, and run on a separate timescale from the hormonal pulse.
What is the half-life of ipamorelin?
Approximately 2 hours in humans, established by population pharmacokinetic-pharmacodynamic modeling in healthy male volunteers given five 15-minute intravenous infusions of 4.21-140.45 nmol/kg [2]. The kinetics were dose-proportional, with clearance 0.078 L/h/kg and steady-state volume of distribution 0.22 L/kg [2]. In rats, plasma clearance is roughly five-fold lower than GHRP-6 [7].
Is ipamorelin available in an oral form?
Not as ipamorelin itself — it is not orally bioavailable and is studied by injection (intravenous, subcutaneous) and intranasally (~20% bioavailability) [7]. Only engineered analogs derived from ipamorelin's scaffold achieved meaningful oral absorption: a peptidomimetic series reached roughly 10% oral bioavailability in dogs [11], and the related oral GHS NN703 reached about 30% in beagles, but these are distinct compounds, not ipamorelin.
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and a selective agonist of the ghrelin / growth hormone secretagogue receptor (GHS-R1a). It releases a growth-hormone pulse from the pituitary without raising ACTH or cortisol even at doses more than 200-fold above its GH ED50 — the first highly GH-selective secretagogue [1]. It is a research peptide, never approved as a drug [3].
What does ipamorelin do for you?
In studies, ipamorelin triggers a single discrete pulse of growth hormone by activating the ghrelin receptor on pituitary cells [1][2]. Its defining feature is selectivity — growth-hormone release without raising cortisol or prolactin [1]. Reported subjective effects (deeper sleep, faster recovery) are anecdotal community accounts, not proven outcomes, and its one human efficacy trial missed its endpoint [3].
What is ipamorelin peptide?
Ipamorelin peptide is a wholly synthetic five-amino-acid chain, formula C38H49N9O5, molecular weight about 711.85 Da, CAS 170851-70-4, derived from GHRP-1 [1]. The non-natural amino acid at position 1 and its D-amino acids resist enzymatic breakdown [1]. It acts as a ghrelin mimetic at GHS-R1a to release growth hormone, and it is a research compound, not an approved drug [3].
What are the risks of ipamorelin?
The honest risk is uncharacterized long-term human safety. Its only controlled human data is a seven-day Phase 2 trial (n=114) that showed no specific safety signal but missed efficacy [3]. Class-level concerns include a cardiotoxicity signal seen with a related GHS-R1a agonist in 28-day rat dosing [6], GH-driven glucose effects [13], and unverified purity of research-grade material [3].
Does ipamorelin reduce belly fat?
No controlled human study shows ipamorelin reduces belly fat. The closest data is a 2024 ferret study where intraperitoneal ipamorelin (1-3 mg/kg) inhibited chemotherapy-induced weight loss by about 24% — preventing loss, not reducing fat [5]. Community reports of gradually leaner body composition over weeks are anecdotal and confounded by diet and training, not clinical evidence [5].
What are the downsides of ipamorelin?
The central downside is the evidence gap: one negative Phase 2 trial [3], no Phase 3, and no long-term human safety database. Class-level signals include a rat cardiotoxicity finding with a related agonist [6] and GH-mediated effects on glucose [13]. Frequently reported anecdotal downsides include post-injection flushing, hunger, water retention, and injection-site irritation.
Why is ipamorelin being discontinued?
Ipamorelin was never an approved drug to discontinue; its clinical development stopped because its only Phase 2 trial (postoperative ileus, NCT00672074) missed its primary endpoint and no Phase 3 followed [3]. Separately, in 2024 the FDA removed ipamorelin acetate from Category 2 of the interim 503A bulk-substances list and reviewed it at an October 2024 advisory meeting, tightening compounding-pharmacy access.
What does CJC-1295 and ipamorelin do?
They act on two different receptors to raise growth hormone: ipamorelin is a ghrelin-receptor (GHS-R1a) agonist (a GHRP), and CJC-1295 is a GHRH analog acting on the GHRH receptor [1]. The pairing is justified by mechanistic complementarity, but the combination itself has never been tested in a controlled trial for any outcome — the evidence is for each compound alone.
Does ipamorelin increase IGF-1?
Not reliably in short studies. In the rat bone-growth study, subcutaneous ipamorelin raised longitudinal bone growth with no measurable change in total IGF-1 [4]. In streptozotocin-diabetic mice it actually went with suppressed IGF-1 alongside hepatic GH-receptor resistance [9]. IGF-1 elevation is more a feature of sustained GH-axis activation than of short ipamorelin exposure.
How does CJC-1295 ipamorelin work?
Each component drives growth-hormone release by a distinct pathway: ipamorelin activates the ghrelin receptor (GHS-R1a) on pituitary cells, while CJC-1295 stimulates the separate GHRH receptor [1]. The two pathways are complementary, which is the mechanistic rationale for combining them. The combination has not been studied in a controlled trial; only the single-agent pharmacology is established [1][2].
How much CJC-1295 ipamorelin should I take?
This site does not provide a human dose, and no studied human dose exists for the combination, which has never been tested in a controlled trial [3]. Single-agent ipamorelin appears in studies at 4.21-140.45 nmol/kg IV (human PK) [2] and 0.03 mg/kg IV twice daily (the failed Phase 2 trial) [3] — study doses by the intravenous route, not recommendations.
Does CJC-1295 ipamorelin work?
The combination has no controlled-trial evidence either way. For ipamorelin alone, the pharmacology works — it reliably releases a growth-hormone pulse [1][2] — but its one human efficacy trial missed its endpoint (25.3 h vs 32.6 h, p=0.15) [3]. A measurable hormone pulse is not the same as a proven clinical benefit, and the combination's clinical efficacy is untested.
Does ipamorelin make you hungry?
It can, mechanistically. Ipamorelin acts on the ghrelin receptor (GHS-R1a), and ghrelin is the body's hunger signal, so increased appetite is a class-level effect [16]. Community reports describe a noticeable uptick in hunger in the hours after injection, characterized as milder than with GHRP-6 but still unwanted for some — an occasionally reported, anecdotal effect, not a clinical measurement.
Will I gain weight on ipamorelin?
No human study answers this directly. Ipamorelin stimulated adiposity and raised leptin in mice independent of growth hormone after two weeks of dosing [15], and it activates appetite-driving ghrelin pathways [16], so weight effects are plausible. Anecdotal community reports vary from leaner body composition to water-retention puffiness. None of this is a controlled human outcome [15].
Does ipamorelin increase appetite?
Mechanistically yes — ghrelin-receptor (GHS-R1a) agonists activate the brain's appetite centers and induce feeding [16]. Ipamorelin is a ghrelin mimetic, so an orexigenic (appetite-stimulating) effect is a class-level signal that its GH selectivity does not cancel. Community reports of increased hunger after injection are consistent with this, though they are anecdotal rather than clinical findings [16].
What does ipamorelin peptide do?
It activates the ghrelin receptor (GHS-R1a) on pituitary cells to release a single pulse of growth hormone, doing so selectively — without raising cortisol or prolactin, which the older peptides in its class did [1]. In animals it also showed effects on bone growth [4] and, at the receptor-class level, on appetite and adiposity [15][16]. It is a research peptide, not an approved medicine [3].
Does ipamorelin cause water retention?
Mild water retention is an occasionally reported anecdotal effect — transient puffiness in fingers, ankles, or face, mostly in the first two to four weeks, described as milder than with older GHRP compounds. Mechanistically it is plausible because growth-hormone excess is associated with sodium and water retention, but no controlled human study has measured fluid effects at research-use doses [3].